Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program —Reply

In Reply We studied the US Food and Drug Administration ’s (FDA’s) oversight and management of an industry-funded prescriber education program aimed at improving prescriber practices and reducing adverse events from use of prescription opioids. Five years into the Risk Evaluation and Mitigation Strategy (REMS) program governing extended release/long- acting (ER/LA) opioids, the FDA was unable to evaluate the effect of the REMS on prescribing behavior or safety outcomes.
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research